ORAL VERSUS IV IRON THERAPY IN PATIENTS WITH KIDNEY DISEASE
- Conditions
- Chronic kidney disease.Anemia in chronic kidney diseaseD63.1
- Registration Number
- IRCT20231003059605N1
- Lead Sponsor
- Pak Emirates Military Hospital Rawalpindi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 210
Inclusion criteria included all male and female patients over the age of 18 years
Not on hemodialysis or erythropoietin diagnosed as anemia with a baseline Hb of less than 13 g/dl in males and less than 12 g/dl in females
With established chronic kidney disease with a GFR (glomerular filtration rate) of less than 60ml/min for more than 90 days assessed using the CKD-EPI equation and/or hyper albuminuria with urine albumin ? 30 mg in 24 hours or urine albumin to creatinine ratio (ACR) ? 30 mg/g.
Exclusion criteria included patients on dialysis, erythropoietin or use of erythropoietin stimulating agents (ESAs) in the last 3 months
Patients with advanced liver, cardiac or ESKD (end-stage kidney disease)
Drug allergies to iron and its supplemental form during therapy or previous known history
Unwilling to be included in the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum iron levels. Timepoint: 4 weeks after starting therapy. Method of measurement: Blood levels.;Serum Hb. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum Ferritin levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum transferrin and TIBC levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.
- Secondary Outcome Measures
Name Time Method Constipation and diarrhea. Timepoint: During 4 weeks of therapy. Method of measurement: Patient history.;Allergy to iron supplementation. Timepoint: During 4 weeks of therapy. Method of measurement: Patient assessment weekly during treatment.